# Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer

> **NCT04358341** · PHASE2 · UNKNOWN · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 136 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** DOXOrubicin Liposome Injection
- **DRUG:** 5fluorouracil

## Key facts

- **NCT ID:** NCT04358341
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-17
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358341, "Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04358341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*